Clinical Trials

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06232655 2025-12-19

Cladribine Venetoclax in Monocytic AML

Phase 2 Recruiting

20 enrolled

Phase 1 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04666649 2025-10-07

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

27 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05745714 2025-09-16

HEM-iSMART C

26 enrolled

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05751044 2025-09-16

HEM-iSMART B

26 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07175415 2025-09-16

HEM-iSMART E

42 enrolled

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04512105 2025-09-11

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

6 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03850574 2025-08-26

TUSCANY

240 enrolled

Phase 1/2 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04086264 2025-08-14

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

218 enrolled

Phase 2 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05182385 2025-07-25

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Phase 1/2 Active not recruiting

30 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Phase 1/2 Completed

24 enrolled 18 charts

Lymphoma, Lymphoma, Follicular, Recurrence

NCT06810778 2025-07-15

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

12 enrolled

Phase 3 Active not recruiting

Leukemia, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT05829226 2025-05-28

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Phase 1 Recruiting

90 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Phase 2 Recruiting

59 enrolled

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

18 enrolled 15 charts

Recurrence, Leukemia, Myeloid, Acute

NCT06742463 2024-12-19

VHAG in Treating R/R T-ALL/LBL

Phase 2 Recruiting

50 enrolled

Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

MyeloidOther hematologic neoplasm

14 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03557619 2024-08-29

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Phase 1 Recruiting

12 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Hematologic Neoplasms

NCT05740449 2024-06-21

HEM-iSMART A

Phase 1/2 Withdrawn

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

LymphoidMyeloidOther hematologic neoplasm

21 enrolled

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03739554 2024-01-25

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

5 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04092179 2024-01-24

ENAVEN-AML

Phase 1/2 Terminated

27 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT03236857 2023-05-22

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

CNSLymphoidOther hematologic neoplasm

143 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Neuroblastoma, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02756611 2023-04-10

VENICE I

Phase 3 Completed

258 enrolled 27 charts

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04809181 2023-02-21

Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients

Phase 2 Unknown

95 enrolled

Recurrence, Hematologic Neoplasms

NCT03484520 2022-12-30

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

48 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Phase 2 Completed

14 enrolled 19 charts

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT03218683 2022-09-23

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

70 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT05522192 2022-08-30

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

70 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02419560 2022-05-24

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

37 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT03886649 2022-04-01

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

7 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT03625505 2021-09-14

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

61 enrolled

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

8 enrolled 12 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT01969695 2019-12-19

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

11 enrolled